web analytics

di Giancarlo Nicoli

As soon as I started to publish the weekly “Dendreon Notable Links”, I got my website hacked! I spent the last three weeks figuring out how to clean it and – especially – how to keep it clean. It’s five days (and counting) scoprire.biz is actually virus free. Now let’s jump in.

26 April 2012 – Video
This one is an earlier link in fact, I saved it for publication as soon as my website was ready.
Michael receiving 2nd leukaphereis treatment:

Some catch-up…
Monday, 7 May 2012
Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth:

Monday, 7 May 2012
Dendreon’s CEO Discusses Q1 2012 Results – Earnings Call Transcript:

Thursday, 9 May 2012
The end game for Biotech – HGSI (DNDN?) – by guam2009lt

Friday, 11 May 2012
Dendreon Management Presents at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference (Transcript):

Saturday, 12 May 2012
Sipuleucel-T Stimulates Response in Localized Setting, Study Finds:

Tuesday, 15 May 2012
To be held on Sunday, May 20, 2012 3:30 PM-5:30 PM
Prostate Cancer: Advanced I Podium
Dendreon Corporation
683: Estimating the overall survival benefit of sipuleucel-T in the IMPACT trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cyropreserved cells
Leonard Gomella
Chadi Nabhan
Todd DeVries
James Whitmore
Mark Frohlich
Daniel George

Tuesday, 15 May 2012
To be held on Monday, May 21, 2012 10:30 AM-12:30 PM
Prostate Cancer: Advanced III Moderated Poster
Dendreon Corporation
953: Sipuleucel-T in African Americans: a subgroup analysis of three phase 3 trials of sipuleucel-T in metastatic castrate resistant prostate cancer
David G. McLeod
David I. Quinn
Jennifer Cullen
James B. Whitmore
Rockville, MD

Wednesday, 16 May 2012
Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting:

Very important data overall.
Abstract #4684: Overall Survival (OS) Benefit with Sipuleucel-T by Baseline PSA; An Exploratory Analysis From the Phase 3
IMPACT Trial, basically says that the earlier a patient gets Provenge, the better are his survival chances.

@ @ @

DNDN website:

Provenge website:

All links are verified and working at date of publication.


Comments are closed.

%d bloggers like this: